The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,314K data for 602K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

180 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.EBI
Universit£ degli Studi di Bari"Aldo Moro"
Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptora/d (PPARa/d) dual agonistic activity.EBI
The University of Tokyo
PPAR Agonists, Compounds, Pharmaceutical Compositions, and Methods of Use Thereof.EBI
Temple University
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.EBI
Bristol-Myers Squibb Co.
Syringaresinol induces mitochondrial biogenesis through activation of PPAR▀ pathway in skeletal muscle cells.EBI
Korea University
Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor▀/d agonists with neuroprotective activity.EBI
Texas Tech University Health Sciences Center
SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR┐ Inhibitor.EBI
Central Pharmaceutical Research Institute
Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria.EBI
Max Planck Institute for Molecular Genetics
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor┐ Modulators.EBI
Goethe-University Frankfurt
Synthesis of 5-trifluoromethyl-2-sulfonylpyridine PPAR▀/d antagonists: Effects on the affinity and selectivity towards PPAR▀/d.EBI
University of Oslo
Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor┐/d agonists.EBI
Sookmyung Women's University
Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.EBI
Goethe-University Frankfurt
Synthesis, biological evaluation and molecular modeling studies of the PPAR▀/d antagonist CC618.EBI
University of Oslo
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).EBI
GlaxoSmithKline
Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-a (PPAR-a) agonists.EBI
National Institute of Pharmaceutical Education and Research (NIPER)
Structural development studies of PPARs ligands based on tyrosine scaffold.EBI
Universit£"G. d'Annunzio"
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for ROR▀ and ROR┐t.EBI
Phenex Pharmaceuticals AG
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.EBI
Goethe-University Frankfurt
Identification of the first potent, selective and bioavailable PPARa antagonist.EBI
Inception Sciences
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.EBI
Glaxo Wellcome Research and Development
Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor¿.EBI
Helmholtz Centre for Infection Research
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.EBI
The University of Sydney
Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.EBI
Pfizer Inc
Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.EBI
Pfizer Inc
Phenoxyacetic acids as PPARd partial agonists: synthesis, optimization, and in vivo efficacy.EBI
GlaxoSmithKline
Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.EBI
GlaxoSmithKline
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.EBI
Istituto Tumori"Giovanni Paolo II"
Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors.EBI
ZAFES/LiFF/OSF Goethe-University Frankfurt
Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-¿B activation and PPAR transcriptional activity.EBI
Chungnam National University
Design, synthesis and in vitro evaluation of a series ofa-substituted phenylpropanoic acid PPAR¿ agonists to further investigate the stereochemistry-activity relationship.EBI
Okayama University
Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.EBI
Trinity College
Activity landscape modeling of PPAR ligands with dual-activity difference maps.EBI
Universidad Nacional Aut£noma de M£xico
Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptord agonists as potent anti-obesity agents in vivo.EBI
Seoul National University
Total synthesis and dual PPARa/¿ agonist effects of amorphastilbol and its synthetic derivatives.EBI
Korea Institute of Science and Technology
Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR)¿ Agonists.EBI
Takeda Pharmaceutical Co., Ltd
Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.EBI
Chungnam National University
Identification of diaryl ether-based ligands for estrogen-related receptora as potential antidiabetic agents.EBI
Johnson & Johnson Pharmaceutical Research and Development LLC
Design, synthesis, and structural analysis of phenylpropanoic acid-type PPAR¿-selective agonists: discovery of reversed stereochemistry-activity relationship.EBI
Okayama University
Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.EBI
Johnson & Johnson Pharmaceutical Research and Development LLC
Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.EBI
Nippon Shinyaku Co. Ltd
SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.EBI
University of Tokyo
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.EBI
Nippon Shinyaku Co. Ltd
Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.EBI
Johnson & Johnson
Design of a partial PPARdelta agonist.EBI
Novo Nordisk A/S
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.EBI
Eli Lilly and Company
Designed multiple ligands. An emerging drug discovery paradigm.EBI
Organon Laboratories
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.EBI
The Scripps Research Institute
Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.EBI
The University of Tokyo
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor¿ (PPAR¿) modulators.EBI
Merck Research Laboratories
A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR)¿ agonists: design and synthesis of benzylpyrazole acylsulfonamides.EBI
Takeda Pharmaceutical Co., Ltd
Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.EBI
Kyorin Pharmaceutical Co., Ltd
Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.EBI
University of Oslo
Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.EBI
The University of Tokyo
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.EBI
The University of Tokyo
Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR)a-selective agonists.EBI
Okayama University
Biological evaluation of novel benzisoxazole derivatives as PPARd agonists.EBI
Nippon Chemiphar Co., Ltd
Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARd agonists.EBI
AstraZeneca R&D Charnwood
Synthesis of a novel human PPARd selective agonist and its stimulatory effect on oligodendrocyte differentiation.EBI
Nippon Chemiphar Co., Ltd
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.EBI
Zydus Research Centre
Selective peroxisome proliferator-activated receptord isosteric selenium agonists as potent anti-atherogenic agents in vivo.EBI
Seoul National University
Improvement of water-solubility of biarylcarboxylic acid peroxisome proliferator-activated receptor (PPAR)d-selective partial agonists by disruption of molecular planarity/symmetry.EBI
The University of Tokyo
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.EBI
Phenex Pharmaceuticals AG
Glycine amides as PPARalpha agonists.EBI
Bayer-Schering Pharma
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).EBI
Bristol-Myers Squibb Co.
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.EBI
The Genomics Institute of the Novartis Research Foundation
Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) delta selective antagonists.EBI
The University of Tokyo
Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.EBI
GlaxoSmithKline
Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists.EBI
Goethe-University Frankfurt
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.EBI
F. Hoffmann-La Roche Inc
Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.EBI
National Health Research Institutes
Selective, potent PPARgamma agonists with cyclopentenone core structure.EBI
Universidade de Vigo
The discovery of equipotent PPARalpha/gamma dual activators.EBI
GlaxoSmithKline
Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.EBI
University of Innsbruck
Highly functionalized 7-azaindoles as selective PPAR gamma modulators.EBI
Merck Research Laboratories
Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.EBI
The University of Tokyo
CoMFA analysis of dual/multiple PPAR activators.EBI
National Institute of Pharmaceutical Education and Research
Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.EBI
GlaxoSmithKline
Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.EBI
Eli Lilly and Company
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.EBI
RE&D VUFB, s.r.o.
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.EBI
Kowa Co.
Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.EBI
University of Tokyo
Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists.EBI
Nagoya City University
Discovery of para-alkylthiophenoxyacetic acids as a novel series of potent and selective PPARdelta agonists.EBI
Johnson and Johnson Pharmaceutical Research and Development
Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.EBI
Pfizer Inc
Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.EBI
Pfizer Inc
Design of potent PPARalpha agonists.EBI
Novo Nordisk A/S
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.EBI
Novo Nordisk A/S
Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.EBI
Bayer Pharmaceuticals Corporation
Design and synthesis of a novel class of dual PPARgamma/delta agonists.EBI
Eli Lilly and Company
Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.EBI
National Health Research Institutes
Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.EBI
Eli Lilly and Company
Studies towards the conception of new selective PPARbeta/delta ligands.EBI
Université d'Orléans
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1.EBI
The Genomics Institute of the Novartis Research Foundation
Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.EBI
F. Hoffmann-La Roche Inc
1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists.EBI
The Genomics Institute of the Novartis Research Foundation
SAR studies: designing potent and selective LXR agonists.EBI
Merck Research Laboratories
Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.EBI
National Health Research Institutes
Design and synthesis of potent and subtype-selective PPARalpha agonists.EBI
Merck Research Laboratories
Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.EBI
National Health Research Institutes
Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.EBI
University of Tokyo
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.EBI
Novartis Institutes for BioMedical Research
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.EBI
Merck Research Laboratories
(2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.EBI
Merck Research Laboratories
Structure-activity relationships of dimeric PPAR agonists.EBI
Novo Nordisk A/S
Benzoyl 2-methyl indoles as selective PPARgamma modulators.EBI
Merck Research Laboratories
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.EBI
Eli Lilly and Company
Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPAR?/? Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.EBI
China Pharmaceutical University
A Photohormone for Light-Dependent Control of PPAR? in Live Cells.EBI
Goethe-University Frankfurt
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.EBI
Research Institute of Tsinghua University
Synthesis and Evaluation of PPAR? Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.EBI
University of Toledo College of Pharmacy and Pharmaceutical Sciences
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.EBI
Merck Research Laboratories
Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.EBI
Eli Lilly and Company
Discovery of the first-in-class dual PPAR?/? partial agonist for the treatment of metabolic syndrome.EBI
Guangdong Pharmaceutical University
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.EBI
Bristol-Myers Squibb
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.EBI
Eli Lilly and Company
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.EBI
Novo Nordisk A/S
Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists.EBI
Merck Research Laboratories
Discovery of novel modulators for the PPAR? (peroxisome proliferator activated receptor ?): Potential therapies for nonalcoholic fatty liver disease.EBI
City of Hope National Medical Center
Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.EBI
China Pharmaceutical University
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.EBI
Kyorin Pharmaceutical Co., Ltd
5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.EBI
Merck Research Laboratories
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).EBI
Lilly Research Laboratories
5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.EBI
Merck Research Laboratories
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.EBI
GlaxoSmithKline
Phenylacetic acid derivatives as hPPAR agonists.EBI
Merck Research Laboratories
Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.EBI
Merck Research Laboratories
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.EBI
Novo Nordisk A/S
Selective PPAR? Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD).EBI
Mitobridge, Inc.
Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPAR?/? Modulators.EBI
Seoul National University
Discovery of 3?,7?,11?-Trihydroxy-6?-ethyl-5?-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.EBI
TES Pharma S.r.l.
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.EBI
Novo Nordisk A/S
Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.EBI
GlaxoSmithKline
Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis.EBI
GlaxoSmithKline
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.EBI
Seoul National University
Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta.EBI
GlaxoSmithKline
Design and Structural Optimization of Dual FXR/PPAR? Activators.EBI
Goethe University Frankfurt
Targeting Peroxisome Proliferator-Activated Receptor Delta (PPAR?): A Medicinal Chemistry Perspective.EBI
Daegu-Gyeongbuk Medical Innovation Foundation
Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.EBI
GlaxoSmithKline
Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPAR? modulators.EBI
Mitobridge, Inc.
Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor ?.EBI
Seoul National University
Discovery of Second Generation ROR? Inhibitors Composed of an Azole Scaffold.EBI
Kyoto Prefectural University of Medicine
Novel Phenyldiazenyl Fibrate Analogues as PPAR ?/?/? Pan-Agonists for the Amelioration of Metabolic Syndrome.EBI
University of Chieti "G. d.Annunzio"
Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor ?/? (PPAR?/?) dual agonists.EBI
The University of Tokyo
Discovery of first-in-class thiazole-based dual FFA1/PPAR? agonists as potential anti-diabetic agents.EBI
Guangdong Pharmaceutical University
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.EBI
Goethe University Frankfurt
The PPARs: from orphan receptors to drug discovery.EBI
Glaxo Wellcome Research & Development
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.EBI
Glaxo Wellcome Research & Development
A Selective Modulator of Peroxisome Proliferator-Activated Receptor ? with an Unprecedented Binding Mode.EBI
Goethe-University Frankfurt
Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPAR? Agonists as Leads for Retinal Disorders.EBI
University of Oklahoma
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.EBI
Terns Pharmaceuticals
Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.EBI
Inception Sciences
Identification of BR101549 as a lead candidate of non-TZD PPAR? agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.EBI
Boryung Pharmaceuticals Co. Ltd.
Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor ?/? Agonist for the Treatment of Primary Biliary Cirrhosis.EBI
WuXi AppTec (Shanghai) Co., Ltd
Diphenylpropane Derivatives as Agonist of PPAR Nuclear Receptors.EBI
Dart Neuroscience LLC
Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.EBI
Okayama University
Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPAR? and PPAR?.EBI
Guangdong Pharmaceutical University
Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-? agonists (SERBAs).EBI
Marquette University
Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor ? agonist.EBI
Daegu-Gyeongbuk Medical Innovation Foundation
Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPAR? selective agonists: New leads for oculovascular conditions.EBI
University of Oklahoma
Novel highly selective peroxisome proliferator-activated receptor ? (PPAR?) modulators with pharmacokinetic properties suitable for once-daily oral dosing.EBI
Mitobridge, Inc.
Indazole-based ligands for estrogen-related receptor ? as potential anti-diabetic agents.EBI
Janssen Research and Development LLC
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR)?/?/? Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.EBI
Inventiva
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor?/? (PPAR?/?) dual agonists.EBI
The University of Tokyo
Polypharmacology of NEBI
Sahmyook University
Triptolide directly inhibits dCTP pyrophosphatase.BDB
Yale University
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.BDB
Virginia Commonwealth University
A fragment-based approach to probing adenosine recognition sites by using dynamic combinatorial chemistry.BDB
University of Cambridge
Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms.BDB
University of Canterbury
Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization.BDB
CNRS
[3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments.BDB
Boots Pharmaceuticals
Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase.BDB
CNRS
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.BDB
Bristol-Myers Squibb Co.